Related Experiment Video
Updated: Apr 29, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
Reply to: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives"
Stephen D Skaper1, Laura Facci, Mariella Fusco
1University of Padua, Padua, Italy, stephen.skaper@unipd.it.
Abstract:
This is a reply to a recently published Commentary: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives" Inflammopharmacology DOI: 10.1007/s10787-014-0202-3 , written in relation to our review article: Skaper SD, Facci L, Fusco M, della Valle MF, Zusso M, Costa B, Giusti P (2014) "Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain" Inflammopharmacology 22:79-94 DOI: 10.1007/s10787-013-0191-7 . We believe that the Commentary by Kriek contains a number of erroneous statements and misinterpretations of the published scientific/medical literature which our reply shall elaborate on. Further, the writer of the Commentary has a direct connection to a company, JP Russell Science Ltd that sells palmitoylethanolamide. The take-home message of our review remains as originally stated: "Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain".
Insights
This reply addresses inaccuracies in a commentary regarding palmitoylethanolamide (PEA). Our review confirms PEA is a promising agent for neuropathic pain and inflammation.
Area of Science:
- Pharmacology
- Pain Management
- Inflammation Research
Background:
- A recent commentary questioned aspects of palmitoylethanolamide (PEA) formulation.
- This commentary related to a review article on PEA as a disease-modifying agent for neuropathic pain.
Purpose of the Study:
- To address erroneous statements and misinterpretations in a published commentary.
- To reaffirm the findings of a review article on palmitoylethanolamide's therapeutic potential.
Main Methods:
- Literature review and critical analysis.
- Response to specific points raised in a commentary.
- Reiteration of evidence supporting palmitoylethanolamide efficacy.
Main Results:
- Identified several erroneous statements and misinterpretations in the commentary.
- Reaffirmed that palmitoylethanolamide is a naturally occurring disease-modifying agent.
- Highlighted potential conflicts of interest in the commentary's author.
Conclusions:
- Palmitoylethanolamide warrants further investigation as a disease-modifying agent.
- PEA shows potential for managing inflammatory responses.
- PEA may be effective in controlling chronic and neuropathic pain.
More Related Videos
07:32Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
06:25Fabrication of Dissolvable Microneedle Patches Loaded with α-Lactalbumin Nanomicelles for Transdermal Capsaicin Delivery and Adipose Tissue Reduction
Published on: December 30, 2025
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioavailability Enhancement: Drug Solubility Enhancement
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Factors Influencing Drug Absorption: Pharmaceutical Parameters